Federal fraudbusters focus on drug pricing while quest for Rx discount card continues
November 1st 2001With the government spending billions to fight terrorism at home and abroad, federal investigators are looking closely at all health care programs for opportunities to stymie abuses and collect big penalties.
Read More
Hepatitis B: An ssessment of current and future treatment options (PDF)
October 1st 2001Interferon alfa-2b and the nucleoside analog lamivudine are the currently available options for treating chronic hepatitis B virus (HBV) infection. This article reviews major efficacy findings with these agents, defines their role according to patients' clinical status, and provides the latest data on optimal duration of therapy, predictors of response, and long-term effects. The authors also explore the emergence of hepatitis B immune globulin for post-liver transplant HBV prophylaxis and offer a progress report on experimental therapies for chronic HBV infection.
Read More
Dalteparin for enoxaparin interchange: Chart review shows promising clinical, economic outcomes
October 1st 2001University Hospital and Medical Center (Tamarac)/University of Florida (Gainesville)-Dalteparin appears to be at least as clinically effective as enoxaparin for the prevention or treatment of the consequences of venous and arterial thromboembolic diseases, say clinicians from these two facilities.
Read More